Extended‐release injectable naltrexone for opioid use disorder: a systematic review

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Addiction

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/add.14180PMID 29396985PMCID PMC5993595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?

  2018cited by this paper
• Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

  2018cited by this paper
• Extended-release naltrexone for opioid use disorder started during or following incarceration.

  2018cited by this paper
• Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

  2018cited by this paper
• Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.

  2018cited by this paper
• Long‐term follow‐up study of community‐based patients receiving XR‐NTX for opioid use disorders

  2017cited by this paper
• Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial

  2017cited by this paper
• Effects of incentives for naltrexone adherence on opiate abstinence in heroin‐dependent adults

  2017cited by this paper
• Addressing the Fentanyl Threat to Public Health.

  2017cited by this paper
• Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

  2017cited by this paper
• Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

  2017cited by this paper
• Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence

  2017cited by this paper
• Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

  2017cited by this paper
• Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial

  2017cited by this paper
• Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis

  2017cited by this paper
• Attitudes, practices, and preparedness to care for patients with substance use disorder: Results from a survey of general internists

  2016cited by this paper
• Ending the Opioid Epidemic - A Call to Action.

  2016cited by this paper
• The Therapeutic Utility of Employment in Treating Drug Addiction: Science to Application.

  2016cited by this paper
• Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone

  2016cited by this paper
• NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

  2016cited by this paper
• Relapse prevention medications in community treatment for young adults with opioid addiction

  2016cited by this paper
• Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

  2016cited by this paper
• Treatment of Opioid-Use Disorders.

  2016cited by this paper
• Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.

  2016cited by this paper
• Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone

  2016cited by this paper
• Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification.

  2016cited by this paper
• A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.

  2016cited by this paper
• Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.

  2016cited by this paper
• Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]

  2016cited by this paper
• Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence

  2015cited by this paper
• Vital Signs: Demographic and Substance Use Trends Among Heroin Users — United States, 2002–2013

  2015cited by this paper
• Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)

  2015cited by this paper
• A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.

  2015cited by this paper
• The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

  2015cited by this paper
• Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions

  2015cited by this paper
• Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

  2015cited by this paper
• Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

  2015cited by this paper
• Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.

  2015cited by this paper
• Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.

  2015cited by this paper
• Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.

  2015cited by this paper
• Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013.

  2015cited by this paper
• Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.

  2015cited by this paper
• Empirical Investigation of SAMHSA’s (Substance Abuse and Mental Health Services Administration) Model of Wellness

  2015cited by this paper
• Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

  2015cited by this paper
• A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.

  2014cited by this paper
• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.

  2014cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2014cited by this paper
• The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study.

  2014cited by this paper
• Injectable and implantable sustained release naltrexone in the treatment of opioid addiction

  2014cited by this paper
• Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

  2014cited by this paper
• Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.

  2014cited by this paper
• Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

  2013cited by this paper
• Extended-Release Intramuscular Naltrexone (VIVITROL®): A Review of Its Use in the Prevention of Relapse to Opioid Dependence in Detoxified Patients

  2013cited by this paper
• Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.

  2012cited by this paper
• Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.

  2012cited by this paper
• Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

  2012cited by this paper
• Cost and utilization outcomes of opioid-dependence treatments.

  2011cited by this paper
• Oral naltrexone maintenance treatment for opioid dependence.

  2011cited by this paper
• Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2009cited by this paper
• Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.

  2008cited by this paper
• Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

  2006cited by this paper
• Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.

  2006cited by this paper
• External validity of randomised controlled trials: "to whom do the results of this trial apply?".

  2005cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2004cited by this paper
• The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.

  1998cited by this paper
• Naltrexone pharmacotherapy for opioid dependent federal probationers.

  1997cited by this paper
• Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals.

  1997cited by this paper

• Exploring the role of community pharmacist-administered injectable naltrexone for drug treatment court participants: Results from a pilot study.

  2026cites this paper
• A Long-acting Naltrexone Implant (iSTEP-N) for Opioid Use Disorder: First-in-Human Phase I Trial.

  2026cites this paper
• Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population.

  2026cites this paper
• Lived Experiences of Medication for Opioid Use Disorder: Clients’ Perspectives on Formulation and Treatment

  2025cites this paper
• Use of nalmefene and behavioral counseling in patients with combined opioid and alcohol dependence

  2025cites this paper
• Genetic Influence on Extended-Release Naltrexone Treatment Outcomes in Patients with Opioid Use Disorder: An Exploratory Study

  2025cites this paper
• Exploring the impact of a medication adherence intervention on recovery and mental health outcomes: A secondary analysis of the MAT-PLUS pilot RCT

  2025cites this paper
• U.S. substance use harm reduction efforts: a review of the current state of policy, policy barriers, and recommendations

  2025cites this paper
• Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl.

  2025cites this paper
• Opioid reward and deep brain stimulation of the lateral hypothalamic area.

  2025cites this paper
• Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS.

  2025cites this paper
• Sustained-release naltrexone for opioid dependence.

  2025cites this paper
• Reward Sensitivity in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study.

  2025cites this paper
• Pain intensity in patients using extended-release naltrexone or opioid agonists and its effect on extended-release naltrexone treatment outcomes.

  2025cites this paper
• Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trials.

  2025cites this paper
• Nonparametric estimation of an optimal treatment rule with fused randomized trials and missing effect modifiers

  2025cites this paper
• High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study

  2025cites this paper
• Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs

  2025cites this paper
• A case–control study on the individualized use of opioid analgesics based on single-nucleotide polymorphism

  2025cites this paper
• Analyzing the Discursive Framing of Medications for Opioid Use Disorder (MOUDs) in U.S. News Media: A Comparative Study of Benefits, Persuasion Methods, and Temporal Trends.

  2025cites this paper
• Thresholds for adjunctive medication usage and probability of initiating injectable naltrexone.

  2025cites this paper
• Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia.

  2025cites this paper
• Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans.

  2024cites this paper
• Remission rates of patients with opioid use disorder who got naltrexone implantation: A retrospective study

  2024cites this paper
• Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study

  2024cites this paper
• Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging

  2024cites this paper
• Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.

  2024cites this paper
• Effect of Relaxation‐Based Virtual Reality on Psychological and Physiological Stress of Substance Abusers Under Detoxification: A Randomized Controlled Trial

  2024cites this paper
• Adverse Events at 1 Month Following Medication Initiation for Opioid Use Disorder Among Adolescents and Young Adults

  2024cites this paper
• A study of predictors of retention to naltrexone maintenance therapy in patients with opioid use disorder: a prospective study

  2024cites this paper
• Considerations when prescribing opioid agonist therapies for people living with HIV

  2024cites this paper
• A retrospective analysis of perioperative medications for opioid‐use disorder and tapering additional postsurgical opioids via a transitional pain service

  2024cites this paper
• Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

  2024cites this paper
• Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.

  2024cites this paper
• Attitudes toward medications for opioid use disorder among peer recovery specialists

  2024cites this paper
• A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone.

  2024cites this paper
• Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations

  2024cites this paper
• County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities

  2024cites this paper
• A Statement on the Pharmacology of Reinstatement: Naltrexone and Relapse to Opioid Seeking

  2024influential citation
• Ambivalence and contingencies: A qualitative examination of peer recovery coaches' attitudes toward medications for opioid use disorder.

  2023cites this paper
• Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

  2023cites this paper
• Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans

  2023cites this paper
• Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.

  2023cites this paper
• Reentry Service Engagement Among a Reentry Population with Co-occurring Mental Health and Opioid Use Disorders in Massachusetts Jails

  2023cites this paper
• Contributions of a central registry to monitor methadone -treatment through the HEALing Communities Study.

  2023cites this paper
• Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis

  2023cites this paper
• Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders.

  2023cites this paper
• Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder

  2023cites this paper
• A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol

  2023cites this paper
• History and current status of contingency management programs in the Department of Veterans Affairs.

  2023cites this paper
• Health care use and cost of treatment for adolescents and young adults with opioid use disorder.

  2023cites this paper
• Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence

  2023cites this paper
• Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone

  2023cites this paper
• Risk of acute care incidents for people treated for opioid use disorder with extended-release naltrexone and buprenorphine

  2023cites this paper
• Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts

  2023cites this paper
• Treating Adolescents With Opioid Use Disorder: A Medication-Assisted Treatment Approach

  2023cites this paper
• Iteration is not solving the opioid crisis, it’s time for transformation

  2023cites this paper
• Transcriptional and epigenetic regulation of microglia in substance use disorders.

  2023cites this paper
• Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study

  2022cites this paper
• The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study

  2022cites this paper
• The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder

  2022cites this paper
• Commentary Article: Defining and Supporting High-Quality Telehealth for Patients with Opioid use Disorder: The Promise and Potential Pitfalls of Telehealth Expansion

  2022cites this paper
• The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis

  2022cites this paper
• Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.

  2022cites this paper
• The association of chronic pain and opioid withdrawal in men and women with opioid use disorder.

  2022cites this paper
• Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone

  2022cites this paper
• Variation in intervention stigma among medications for opioid use disorder

  2022cites this paper
• Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers

  2022influential citation
• Care of Justice-Involved Populations.

  2022cites this paper
• Discordance in Addressing Opioid Crisis in Rural Communities: Patient and Provider Perspectives

  2022cites this paper
• Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor

  2022cites this paper
• Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.

  2022cites this paper
• Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative

  2022cites this paper
• Duration of Medication Treatment for Opioid-Use Disorder and Risk of Overdose among Medicaid Enrollees in Eleven States: A Retrospective Cohort Study.

  2022cites this paper
• Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders

  2022cites this paper
• The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review

  2022cites this paper
• Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials

  2022cites this paper
• A national survey of state laws regarding medications for opioid use disorder in problem-solving courts

  2022cites this paper
• Sustained drug delivery strategies for treatment of common substance use disorders: Promises and challenges.

  2022cites this paper
• HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial

  2022influential citation
• Potential of Methocinnamox to Treat Opioid Misuse

  2022cites this paper
• Perioperative Opioids, the Opioid Crisis, and the Anesthesiologist

  2022cites this paper
• Provider Perceptions of Medication for Opioid Used Disorder (Moud): A Qualitative Study in Communities with High Opioid Overdose Death Rates

  2022cites this paper
• Self-Reported Treatment Need and Barriers to Care for Adults With Opioid Use Disorder: The US National Survey on Drug Use and Health, 2015 to 2019.

  2022cites this paper
• Effect of fabrication parameters on morphology and drug loading of polymer particles for rosiglitazone delivery.

  2021cites this paper
• Opioids and the Criminal Justice System: New Challenges Posed by the Modern Opioid Epidemic

  2021cites this paper
• Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.

  2021cites this paper
• Functional evaluation of NK1 antagonism on cue reactivity in opiate dependence; An fMRI study

  2021cites this paper
• Recent Advances in the Treatment of Opioid Use Disorder

  2021cites this paper
• Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial

  2021cites this paper
• Cost-effectiveness of Treatments for Opioid Use Disorder.

  2021cites this paper
• Who Gets Medication-assisted Treatment for Opioid Use Disorder, and Does It Reduce Overdose Risk? Evidence from the Rhode Island All-payer Claims Database

  2021cites this paper
• Approaches to the Development of a Low-dose Naltrexone Preparation in the Form of a Nasal Spray (Review)

  2021cites this paper
• Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

  2021cites this paper
• Opioid use disorder treatment for people experiencing homelessness: A scoping review

  2021cites this paper
• Treatment of opioid use disorder in primary care

  2021cites this paper
• Effect of Extended-Release Naltrexone on Alcohol Consumption: A Systematic Review and Meta-analysis.

  2021cites this paper
• Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder.

  2021cites this paper
• Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees.

  2021cites this paper
• Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?

  2021cites this paper